J&J to Ask FDA to Approve Its COVID-19 Booster Shot

MONDAY, Oct. 4, 2021 (HealthDay News) -- Johnson & Johnson plans to ask the U.S. Food and Drug Administration to approve emergency use of a booster shot of its single-dose COVID-19 vaccine early this week.

While the request has yet to be submitted, the FDA on Friday scheduled an Oct. 15 meeting of its expert advisory panel to discuss whether a booster shot of the vaccine should receive emergency use authorization, The New York Times reported.

The scheduling of that meeting before Johnson & Johnson has even filed its application with the FDA highlights the Biden administration's concerns that the 15 million Americans who received the company's vaccine require more protection, The Times said. Johnson & Johnson is the last of the three FDA-authorized vaccine providers to seek approval of booster shots, as increasing evidence suggests that older adults and other high-risk people may need them.

A recent U.S. Centers for Disease Control and Prevention study found that the Johnson & Johnson vaccine was only 71 percent effective against hospitalization from COVID-19 compared with 88 percent for the Pfizer vaccine and 93 percent for the Moderna vaccine. Both are two-dose vaccines. Johnson & Johnson recipients were also more likely to have breakthrough infections or symptomatic COVID-19 than recipients of the other two vaccines, other research has shown, The Times reported. But a company-funded study of nearly 2 million people showed the vaccine was 81 percent effective against hospitalization. And other studies suggest that protection from the Johnson & Johnson vaccine does not wane over time like protection from the Pfizer vaccine does.

Regardless, the company announced last month that a second dose, given two months after the first, increased the vaccine's effectiveness against symptomatic COVID-19 by about 22 percentage points, to 94 percent. Johnson & Johnson also said two shots were 100 percent effective against severe disease, although that estimate was less conclusive, The Times reported.

The New York Times Article